HGEN - Humanigen inks manufacturing deal with Thermo Fisher for lenzilumab

Humanigen (HGEN) has collaborated with Thermo Fisher Scientific (TMO) to expand the manufacturing capacity for lenzilumab, for use in COVID-19, to support a potential Emergency Use Authorization ((EUA)). "Manufacturing preparation, precision and expertise are critical as we execute on an aggressive strategy, pending a potential EUA from the FDA, to deliver a COVID-19 therapeutic this winter that has the potential to reduce the risk of ventilation or death and send patients home from the hospital earlier," said Cameron Durrant, MD, MBA, CEO.Thermo Fisher will begin the technical transfer of the lenzilumab bulk drug substance process and commercial scale production could begin before year end.HGEN up 7% premarket.

For further details see:

Humanigen inks manufacturing deal with Thermo Fisher for lenzilumab